US FDA Makes Flexibility Look Routine In TB Drug Review, But Not Everyone Is Pleased
Executive Summary
The most remarkable aspect of the positive advisory committee for pretomanid is how routine FDA’s flexibility in the face of unmet need is starting to feel – but there are some dissenting voices that merit attention.
You may also be interested in...
Pretomanid Gets Panel Endorsement As Part Of Regimen, Not Individual Molecule, For Treatment-Resistant Tuberculosis
US FDA's Antimicrobial Drugs Advisory Committee made clear that its positive 14-4 approval vote was supportive of the TB Alliance's pretomanid as part of a regimen for treatment-resistant tuberculosis since the role of each active ingredient in the combination is not adequately understood.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.